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The short- and long-term effects of two calcium channel 
blocking drugs, verapamil and nifedipine, on blood pres•
sure, heart rate, plasma catecholamines, plasma renin 
activity, plasma volume and cardiac performance (echo•
cardiography) were studied in essential hypertensive pa•
tients and in normal subjects. Verapamil, 160 mg orally, 
reduced blood pressure within 60 minutes in 22 hyper•
tensive patients, but not in 12 normotensive subjects. 
Nifedipine, 10 mg sublingually, reduced blood pressure 
within 15 minutes in 19 hypertensive patients, but not 
in 7 normotensive subjects. Plasma noradrenaline was 
significantly increased both in normal subjects and in 
hypertensive patients only after nifedipine was admin•
istered. Verapamil (80 mg three times a day) first, and 
nifedipine (10 mg three times a day) thereafter, or vice 
versa, were given to 12 hospitalized hypertensive pa•
tients on a fixed sodium and potassium intake; the drugs 
produced similar blood pressure reductions, but heart 
Hypertension is a hemodynamic disorder in which periph•
eral vascular resistance is inappropriately elevated for any 
given level of cardiac output (1,2). Hence, the administra•
tion of oral vasodilating drugs may be considered the most 
logical and specific approach to the treatment of essential 
hypertensive patients. However, the use of commonly avail•
able vasodilators is often associated with undesired side 
effects related to reflex stimulation of the sympathetic and 
renin-angiotensin systems (3-5). 
Calcium antagonist drugs constitute a new class of com•
pounds which have been effective in the treatment of hy-
From the Department of Clinica Medica, University of Brescia, BreSCIa 
and the *Institute of Cardiology, University of Perugia, Perugia, Italy. 
This work was supported In part by Grants 81.00416.83, 82.02249.565 
and 83.02750.56 from the NatIOnal Research CounCIl, Rome, Italy. 
Manuscript received August 13, 1984; revised manuscript received July 
30, 1985, accepted October 7, 1985. 
Address for reprints: Enrico AgabitI-Rosei, MD, Clinica Medica Uni•
vefSIty of Brescia, c/o I Divisione Medicina, Spedali Civil!, 251 ()() BreSCIa, 
Italy. 
© 1986 by the Amencan College of CardIOlogy 
rate and plasma catecholamines were increased only after 
nifedipine (p < 0.05). Neither drug affected plasma vol•
ume, aldosterone or plasma renin activity. 
Long-term ambulatory treatment with verapamil (80 
or 160 mg three times a day for 2 to 4 months) or ni•
fedipine (10 mg three times a day for 2 months) produced 
changes in all variables that were similar to those ob•
served in the hospital (controlled) study. Shortening 
fraction was significantly increased after nifedipine 
(p < 0.05) but no change was observed after verapamil. 
In conclusion, 1) blood pressure is effectively reduced 
by both verapamil and nifedipine; 2) an appreciable ad•
renergic stimulation may be caused by nifedipine, but 
usually not by verapamil, and 3) fluid retention, renin 
release or myocardial depression is not observed during 
verapamil or nifedipine treatment. 
(J Am Coli CardioI1986;7:916-24) 
pertension (6-10). In addition to a significant reduction of 
peripheral vascular resistance, a direct myocardial depres•
sant effect of these drugs cannot be excluded; in fact, cal•
cium antagonists interfere with an excitation-induced dis•
placement of calcium into both myocardial and smooth muscle 
cells (11-13). Although nifedipine and verapamil both lower 
blood pressure, they have different structural, pharmaco•
logic and electophysiologic properties (14,15). 
The aim of this study was to investigate and compare 
the short- and long-term effects of nifedipine and verapamil 
on blood pressure, heart rate, plasma catecholamines, plasma 
renin activity, aldosterone, plasma volume and cardiac per•
formance in a group of patients with mild to moderate pri•
mary hypertension. 
Methods 
Study patients. Fifty-three patients (32 male and 21 
female, age range 22 to 58 years, mean 38) with primary 
hypertension and 15 healthy normotensive volunteers (9 
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male and 6 female, age range 24 to 41 years, mean 30) gave 
their informed consent to the study. In all hypertensive 
patients, diastolic blood pressure was 95 mm Hg or greater 
(systolic blood pressure and diastolic blood pressure ranged 
from 150 to 190 and from 95 to 130 mm Hg, respectively). 
All patients were in stage I or II of the WHO classification 
(16), Causes of secondary hypertension were excluded by 
routine investigations, Previous treatment was discontinued 
at least 4 weeks prior to the study, 
Study protocol. There were three different protocols. 
Acute (hospital) study. The short-term effect of vera•
pamil or nifedipine on blood pressure (auscultatory method, 
phase V), heart rate, plasma catecholamines and plasma 
renin activity was assessed. Verapamil or nifedipine was 
given in a single-blind test to hospitalized hypertensive pa•
tients and normotensive volunteers; the studies were per•
formed in the morning with the patient supine and after 
overnight fasting. Verapamil. 160 mg orally, was given to 
22 hypertensive patients (15 male and 7 female, age range 
28 to 44 years, mean 35) and 12 normal subjects (8 male 
and 4 female, age range 25 to 41 years, mean 32). Blood 
pressure and heart rate were checked every 15 minutes and 
blood for plasma renin activity, noradrenaline and adrena•
line estimation was drawn after 30, 60, 120 and 180 min•
utes. Nifedipine, 10 mg sub lingually , was given to 19 hy•
pertensive patients (9 male and 10 female, age range 22 to 
55 years, mean 38) and 7 normotensive subjects (4 male 
and 3 female, age range 18 to 28 years, mean 25), Blood 
pressure and heart rate were measured every 15 minutes and 
blood for plasma renin activity, noradrenaline and adrenaline 
estimation was drawn after 30, 60, 120 and 180 minutes. 
Controlled (hospital) study, Twelve hypertensive pa•
tients (6 male and 6 female, age range 28 to 58 years, mean 
42) were hospitalized and maintained on a diet with a fixed 
sodium and potassium content (120 and 80 mEq/24 hours, 
respectively), After 5 days of placebo washout. verapamil 
(80 mg three times a day orally) first and then nifedipine 
(10 mg three times a day orally) or vice versa, according 
to a random sequence, were given in a single-blind test, 
each for 8 days, with an interval of 5 days between the two 
treatments, During the 5 day interval, placebo was given 
and the electrolyte diet content was kept constant. Every 
day before and during treatment, blood pressure and heart 
rate, in supine and standing positions, were repeatedly mea•
sured, Plasma catecholarnines, plasma renin activity, plasma 
aldosterone, in supine and standing positions, and plasma 
volume were measured before and at the end of each treat•
ment period with verapamil and nifedipine, In this study 
only data obtained before dosing are reported. Routine ex•
amination included electrocardiography, chest X-ray films, 
and standard hematologic and biochemical assessment. 
Chronic study, Three groups of hypertensive patients 
(WHO class I and II) were given, respectively, verapamil, 
80 mg three times a day orally (10 patients of the group 
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included in the controlled study, 5 male and 5 female, age 
range 28 to 55 years, mean 40); verapamil. 160 mg three 
times a day orally (18 patients of the group that was included 
in the acute study, 13 male and 5 female, age range 28 to 
44 years, mean 36); and nifedipine, 10 mg three times a 
day orally (12 patients, 7 male and 5 female, of the group 
included in the acute study, age range 26 to 55 years, mean 
41). They were reexamined as outpatients every 2 weeks, 
After 2 to 4 months they were readmitted and blood pres•
sure, heart rate, plasma renin activity and plasma cate•
cholamines in supine and in standing positions were mea•
sured again on the morning before and 2 hours after 
administration of the drug, In this study, however, only data 
obtained before dosing are reported. 
Echocardiographic measurements. In some of these 
patients an echocardiographic study was performed before 
and after treatment with nifedipine or verapamiL The pa•
tients were selected on the basis of echographic tracings of 
very good quality. M-mode echocardiograms (two-dimen•
sionally directed) were performed using a SKI Ekosector 
lor SKI 5000 instrument in 10 patients (4 male and 6 female, 
age range 28 to 57 years) before and after 20 to 30 days 
(mean 23) of effective verapamil treatment (80 or 160 mg 
three times a day) and in 7 patients (4 male and 3 female, 
age range 34 to 52 years) before and after 10 to 20 days 
(mean 17) of effective nifedipine treatment (10 mg three 
times a day). All subjects were studied in the morning, after 
at least 30 minutes of supine rest in the postabsorptive state, 
in the left lateral decubitus position, before dosing. All 
records were obtained under two-dimensional control that 
allowed an accurate localization of the measurement plane. 
In this study we considered the end-diastolic and end-sys•
tolic left ventricular dimensions, the shortening fraction and 
the mean velocity of fiber shortening. All measurements 
were made according to the standardized method of the 
American Society of Echocardiography (17). 
The echocardiograms were pooled and coded after com•
pletion of the study and interpreted by two observers (ML 
Muiesan and G Romanelli); the average of the results ob•
tained by the two interpreters, the differences being never 
higher than 10%, was used for each echocardiographic vari•
able. 
Plasma assay. Plasma catecholamines were measured 
by the method of Renzini et aL (18) which gives results 
almost identical to those obtained by enzymatic methods. 
In our experience (19) values of plasma catecholamines 
determined simultaneously by our ftuorimetric technique 
and by the DaPrada radio enzymatic technique (20) are 
closely related (r = 0.96 and 0.78, respectively). Intraassay 
and interassay mean variation coefficients of the ftuorimetric 
technique are, respectively, 8 and 14% for noradrenaline 
and 13 and 20% for adrenaline. Plasma renin activity and 
plasma aldosterone were measured by radioimmunoassaay 
(21.22). Evans Blue was used for plasma volume measure-
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ment, with blood sampling after a 10 minute equilibration 
period (23)_ Routine hematologic and biochemical mea•
surements were obtained using a Technicon Autoanalyzer. 
Statistical analysis. Standard statistical tests were used 
to calculate significances between variables (paired Stu•
dent's t test) and to assess the significance of correlation 
between variables_ The data are expressed as mean ± stan•
dard deviation. Two-tailed probability values are given to 




Effect of verapamil administration (Fig. 1). In the 22 
hypertensive patients 160 mg of verapamil induced a prompt 
reduction of blood pressure, which achieved its maximum 
at 60 minutes (from 168/103 ± 12/6 to 143/88 ± 15111 
mm Hg, p < 0.001) and was maintained for at least 4 hours. 
At 60 minutes diastolic blood pressure was 95 mm Hg or 
less in 18 of the 22 patients. Despite this hypotensive effect, 
heart rate, plasma catecholamines and plasma renin activity 
Figure 1. Changes in blood pressure (BP), heart rate (HR), plasma 
rehin activity (PRA) and plasma catecholamines (CAT) at 30,60, 
120 and 180 minutes after verapamil administration (160 mg orally) 
in 22 hypertensive patients and 12 normal volunteers. *p < 0.05; 
**p < 0.01; ***p < 0.001. 
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Figure 2. Changes in blood pressure (BP), heart rate (HR), plasma 
renin activity (PRA) and plasma catecholamines (CAT) at 30,60, 
120 and 180 minutes after nifedipine administration (l0 mg sub•
lingually) in 19 hypertensive patients and 7 normal volunteers. 
*p < 0.05; **p < 0.01; ***p < 0.001. 
remained substantially unmodified. On average, no signif•
icant change in blood pressure, heart rate, plasma renin 
activity and plasma catecholamines was observed in the 
nonnotensive subjects, although in some of them the blood 
pressure was reduced after 60 minutes (maximal reduction 
20 mm Hg for systolic blood pressure and 10 mm Hg for 
diastolic blood pressure in two subjects). 
Effect of nifedipine administration (Fig. 2). Nifedipine, 
10 mg sublingually, reduced the blood pressure within 15 
minutes in the 19 hypertensive patients. The reduction of 
blood pressure was associated with a significant increase of 
plasma noradrenaline (from 172 ± 96 to 254 ± 105 nglliter 
at 30 minutes, p < 0.01). The maximal reduction of blood 
pressure occurred at 30 minutes (basal 168 ± 12110 mm 
Hg, at 15 minutes 1541100 ± 12/8 mm Hg, at 30 minutes 
148/95 ± 1417 mm Hg, p < 0.001 systolic and p < 0.01 
diastolic). At 30 minutes diastolic blood pressure was 95 
mm Hg or less in 12 of the 19 patients. Plasma renin activity 
and heart rate were slightly, but not significantly, increased. 
On average, blood pressure was not significantly reduced 
by nifedipine in seven nonnotensive subjects, while heart 
lACC Vol 7, No 4 
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rate, plasma renin activity and noradrenaline were signifi•
cantly increased (at 30 minutes, heart rate from 67 ± 7 to 
79 ± 10 beats/min, p < 0.05, noradrenaline from 147 ± 
32 to 282 ± 74 ng/liter, p < 0.001, plasma renin activity 
from 1.7 ± 1.3 to 5 ± 2.6 ng/ml per h, p < 0.01). The 
increase in heart rate, noradrenaline and plasma renin ac•
tivity was greater and more prolonged in the normotensive 
subjects compared with the hypertensive patients (average 
percent increase at 30 minutes in normal SUbjects: heart rate 
+ 18%, noradrenaline +92%, plasma renin activity +294%; 
in hypertensive patients: heart rate + 9%, noradrenaline 
+48%, plasma renin activity +66%). 
Controlled Study 
Blood pressure and heart rate (Fig. 3). Both verapamil 
and nifedipine reduced systolic and diastolic blood pressure 
in the 12 patients; the reductions were significant on the 
first day of treatment (p < 0.01 and p < 0.001, respectively) 
and were maintained throughout the study (p < 0.001). The 
antihypertensive effect of the two agents was comparable 
(basal blood pressure 164/106 ± 15110 supine and 
1611111 ± 14110 mm Hg standing; blood pressure after 
verapamil141/91 ± 8/6 supine and 138/95 ± 10/5 mm Hg 
standing; blood pressure after nifedipine 138/90 ± 9/9 su•
pine and 129/88 ± 11110 mm Hg standing). Supine diastolic 
blood pressure was 95 mm Hg or less in 8 of the ) 2 patients 
during both verapamil and nifedipine treatment. 
Heart rate was not significantly affected by verapamil, 
whereas it increased significantly after nifedipine; on the 
first day of treatment the increase of heart rate induced by 
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nifedipine was significant in both supine (from 74 ± 6 to 
82 ± 4 beats/min, p < 0.001) and standing (from 84 ± 8 
to 98 ± 7 beats/min, p < 0.001) positions, but at the end 
of the study a statistical significance was observed only in 
the standing position (from 84 ± 8 to 96 ± 8 beats/min, 
p < 0.01). 
Plasma catecholamines and renin activity. Plasma 
catecholamines were not affected by treatment with vera•
pamil; on the contrary, supine and standing noradrenaline 
as well as standing adrenaline increased (p < 0.01 and 
p < 0.05, respectively) after nifedipine administration. Su•
pine and standing plasma renin activity and plasma aldo•
sterone were not significantly affected by verapamil or ni•
fedipine administration (Table 1). 
There was no correlation between age or basal blood 
pressure and the hypotensive effect of these drugs. There 
was a significant inverse correlation (r := 0.58 and 0.55, 
p < 0.05) between basal plasma renin activity and the hy•
potensive effect of verapamil and nifedipine, respectively. 
Nifedipine and verapamil did not induce significant changes 
in plasma volume or body weight (basal plasma volume 
18.9 ± 2.8, after nifedipine 19.4 ± 2.4, after verapamil 
19.2 ± 3.4 mllcm2 ; basal body weight 71.3 ± 6.6, after 
nifedipine 70.4 ± 6.6, after verapamil 70.8 ± 8.2 kg), 
Chronic Study 
Verapamil 80 mg three times a day (Fig. 4). After 4 
months of treatment with verapamil at the lower dosage 
blood pressure was significantly reduced (from 1641106 ± 
14111 to 143/96 ± 1118 mm Hg [p < O.oI systolic and p 
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Figure 3. Daily average values of 
blood pressure (BP) and heart rate (HR) 
in 12 hypertensive patients treated with 
verapamil (80 mg three times a day) 
and nifedipine (10 mg three times a 
day). Statistical significance is given 
only for the first and the eighth day 
of treatment. **p < 0.01; ***p < 
0.001. 
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Table J. Plasma Catecholamines, Plasma Renin Activity and Plasma Aldosterone Before and After 8 Days of Verapamil or 
Nifedipine Treatment in the Controlled Study 
Basal Verapamil Nifedipine 
Supine Standing Supine Standing Supine Standing 
Noradrenaline (ng/liter) 156 ± 45 311 ± 120 194 ± 80 352 ± 164 297 ± 158** 500 ± 243* 
Adrenaline (ng/liter) 69 ± 44 86 ± 47 82 ± 35 90 ± 58 92 ± 40 185 ± 149* 
Plasma renin activity 1,6 ± 1,5 3,7 ± 3.4 I.2±U 3.0 ± 2.8 2.5 ± 1.4 4.2 ± 2.1 
(ng/ml per h) 
Aldosterone (ng/liter) 92 ± 54 203 ± 98 95 ± 92 145 ± 83 64 ± 20 128 ± 85 
*p < 0.05; **p < 0.01; significance of difference in respect to basal values. Data are means ± SO. 
< 0.05 diastolic] supine, and from 1611110 ± 14110 to 
144/98 ± 14/9 mm Hg [p < 0.05] standing). Supine dia•
stolic blood pressure was 95 mm Hg or less in 7 of the 10 
patients. Heart rate did not change significantly in the supine 
position, while it was reduced in the standing position (p 
< 0.01). Plasma catecholamines and plasma renin activity 
remained substantially unchanged. 
Verapamil 160 mg three times a day (Fig. 4). After 
2 months of treatment with verapamil at the higher dosage 
blood pressure was significantly reduced (from 171/108 ± 
13113 to 129/88 ± 13110 mm Hg [p < 0.001] supine, and 
Figure 4. Changes in supine (open bars and circles) and standing 
(solid bars and triangles) blood pressure (BP), heart rate (HR), 
plasma renin activity (PRA) and plasma catecholamines (CAT) 
after chronic verapamil treatment, 80 mg three times a day for 4 
months in 10 patients and 160 mg three times a day for 2 months 
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from 1661110 ± 12113 to 127/89 ± 14111 mm Hg [p < 
0.001] standing) and this reduction was greater than that 
observed at the lower dosage. Supine diastolic blood pres•
sure was 95 mm Hg or less in 15 of the 18 patients. Heart 
rate was not significantly affected by verapamiI. Plasma 
noradrenaline was slightly, but significantly increased (from 
158 ± 76 to 230 ± 102 ng/liter [p < 0.05] supine, from 
240 ± 132 to 390 ± 226 ng/liter [p < 0.05] standing) 
while no significant change was observed in plasma adren•
aline and plasma renin activity. 
Nifedipine 10 mg three times a day (Fig. 5). After 2 
months of treatment with nifedipine, 10 mg three times a 
day, blood pressure was significantly reduced (from 168/108 
± 12/10 to 149/96 ± 1417 mm Hg [p < 0.01] supine, 
and from 1621108 ± 13/10 to 147/93 ± 13/8 mm Hg 
[p < 0.01 systolic and p < 0.001 diastolic] standing). Su•
pine diastolic blood pressure was 95 mm Hg or less in 6 of 
the 12 patients. Heart rate was unchanged in the supine 
position, but increased significantly on standing (from 79 
± 10 to 89 ± 10 beats/min) (p < 0.05). Supine and standing 
plasma noradrenaline levels were significantly increased (from 
203 ± 62 to 333 ± 139 ng/liter [p < 0.01] supine, and 
from 334 ± 73 to 448 ± 146 ng/liter [p < 0.05] standing). 
Plasma adrenaline and plasma renin activity remained sub•
stantially unchanged. 
Echocardiographic findings (Table 2). The effects of 
verapamil and nifedipine on left ventricular internal dimen•
sions and some indexes of left ventricular performance 
(shortening fraction and mean velocity of circumferential 
fiber shortening) were studied. During treatment with ni•
fedipine the reduction of blood pressure was associated with 
a significant increase in shortening fraction (p < 0.05) and 
a significant reduction in end-systolic dimension (p < 0.05). 
On the other hand, verapamil did not affect the indexes of 
left ventricular performance and left ventricular internal di•
mensions. 
Side effects. In the acute study, three hypertensive pa•
tients and two normal subjects complained of flushing after 
the administration of verapamiI. Six hypertensive patients 
and two normal subjects complained of headache and flush•
ing after the acute administration of nifedipine. 
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Figure 5. Changes in supine (open bars and circles) and standing 
(solid bars and triangles) blood pressure (BP), heart rate (HR), 
plasma renin activity (PRA) and plasma catecholamines (CAT) 
after chronic nifedipine treatment, 10 mg three times a day for 2 
months in 12 patients. *p < 0.05; **p < 0.01; ***p < 0.001. 
In the controlled study, two patients started the trial, but 
were withdrawn during treatment with nifedipine because 
of headache and tachycardia, and were not considered in 
the analysis of results. 
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During long-term treatment with verapamil, one patient 
had a temporary skin rash and three complained of mild 
constipation. None interrupted the study. No electrocardio•
graphic abnormalities were recorded. During long-term 
treatment with nifedipine five patients complained of pal•
pitation, facial flushing and headache and two patients had 
slight ankle edema; all these symptoms were of a mild 
degree and withdrawal of treatment was not necessary. 
Discussion 
Rationale for use of calcium antagonists in essential 
hypertension. A derangement in transmembranous sodium 
and calcium transport has been proposed as a possible ex•
planation for the pathogenesis of essential hypertension (24). 
An elevated intracellular sodium concentration has been 
considered to lead to an increased arteriolar tone by raising 
intracellular free calcium concentrations, that finally deter•
mines vascular tone and reactivity (25). In patients with 
essential hypertension, free calcium concentration in plate•
lets has been found elevated and directly related to the height 
of blood pressure (26). In addition, an enhanced vasodilation 
resulting from regional infusion of the calcium antagonists, 
verapamil, nicardipine and nitrendipine, has been demon•
strated in hypertensive patients as compared with normo•
tensive subjects (27,28). Furthermore, a greater sensitivity 
to extracellular calcium as well as a greater relaxation in 
the presence of verapamil and nifedipine have also been 
demonstrated in blood vessels from spontaneously hyper•
tensive as compared with normotensive rats (29-31). It may 
be, therefore, that calcium antagonists may act by correcting 
a primary or secondary defect of cellular calcium metabo•
lism in essential hypertension. 
Effects ofverapamil and nifedipine on blood pressure, 
heart rate and plasma catecholamine concentration. Our 
study has clearly confirmed that verapamil and nifedipine 
are effective and well tolerated agents for the reduction of 
arterial pressure both in the short- and long-term treatment 
of essential hypertensive patients. These results are in agree•
ment with those obtained in previous investigations by our•
selves and others (6-9). It is of interest that average blood 
pressure was not significantly reduced in normal subjects 
after the acute administration of verapamil and nifedipine; 
Table 2. Effects of Verapamil or Nifedipine Treatment on Blood Pressure, Heart Rate and Some Echocardiographic Variables 
MAP (mmHg) HR (beats/min) EDD (mm) ESD (mm) SF(%) VcF (circ/s) 
Basal (n = 10) 127 ± 8 76 ± 12 49 ± 5 31 ± 5 37 ± 5 1.1 ± 0.3 
Verapamilt 110 ± 5*** 69 ± 9 48 ± 6 30 ± 6 38 ± 6 1.1 ± 0.2 
Basal (n = 7) 130 ± 8 73 ± 6 49 ± 3 32 ± 3 35 ± 4 1.2 ± 0.3 
Nifedipine:j: 113 ± 4*** 79 ± 11* 48 ± 3 28 ± 2* 42 ± 4* 1.5 ± 0.2 
*p < 0.05; ***p < 0.001; significance of difference in respect to basal values t80 or 160 mg for 20 to 30 days; :j:1O mg three times a day for 10 
to 20 days. circ = CIrcumferences; EDD = end-diastolIc dimenSIOn; ESD = end-systolic dimension, HR = heart rate; MAP = mean arterial pressure; 
SF = shortemng fraction; VcF = mean velocity of circumferential fiber shortening. 
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in fact, although in some nonnal subjects blood pressure 
was slightly reduced, any hypotensive effect in them was 
consistently lower as compared with that observed in hy•
pertensive patients. 
Adrenergic activity. Despite the fact that both verapamil 
and nifedipine similarly reduced blood pressure in hyper•
tensive patients and did not modify blood pressure in nonnal 
subjects, their effect on adrenergic activity, as evaluated by 
plasma catecholamine concentrations, was not the same. 
Plasma noradrenaline was significantly increased after ni•
fedipine administration both in hypertensive patients and in 
nonnal subjects, while it did not change after verapamil 
administration. Nifedipine administration increased heart rate, 
but verapamil acute administration did not. In the short•
tenn crossover controlled study, the effects of verapamil 
and nifedipine on blood pressure, heart rate and plasma 
catecholamines were directly compared in hypertensive pa•
tients. We observed that verapamil and nifedipine, at the 
dosage given in this study, induced comparable reductions 
of blood pressure. However, the treatment with verapamil 
did not induce any measurable increase in sympathetic ac•
tivity, while nifedipine administration was associated with 
adrenergic stimulation, as reflected by a significantly higher 
standing heart rate and by significantly greater plasma cate•
cholamine concentrations. After long-tenn therapy with ve•
rapamil or nifedipine, blood pressure remained significantly 
lower compared with basal values, and therefore the emer•
gence of tolerance was not a problem with these drugs. 
Heart rate changes resulted that were similar to those ob•
served in the short-tenn study, that is, heart rate was sig•
nificantly increased in standing position during the treatment 
with nifedipine in these patients. Plasma noradrenaline re•
mained elevated after prolonged nifedipine treatment. In•
creasing the dosage of verapamil caused a more marked 
antihypertensive effect, together with an increase in plasma 
noradrenaline of only weak statistical significance. How•
ever, also in the chronic study at a comparable level of 
blood pressure reduction, treatment with nifedipine was fol•
lowed by a significantly greater adrenergic stimulation in 
respect to treatment with verapamil. 
This different behavior of the two agents might be related 
to the fact that nifedipine is probably a more potent pe•
ripheral vasodilator than verapamil, and therefore induces 
a greater baroreflex stimulation of the sympathetic nervous 
system. Another conjectural explanation is that nifedipine 
acts mainly on the arteriolar bed, while the dilating action 
of verapamil extends to the veins, thus reducing venous 
return and cardiac stimulation (32). In addition, verapamil 
and nifedipine differ from each other not only in their chem•
ical structure, but also in the mechanisms by which they 
interfere with the entry of calcium into the cell (33), and 
possibly also in the calcium-dependent mechanisms of nor•
adrenaline metabolism and release at the postganglionic nerve 
endings. In our experience with many other vasodilating 
lAce Vol 7. No -+ 
Aprd 1986916-24 
drugs, only captopril does not increase plasma catechol•
amines (34). 
In contrast to the result of other studies (35), we have 
not observed a correlation between basal blood pressure or 
age and the hypotensive effect of verapamil and nifedipine. 
It must be observed, however, that the range of basal blood 
pressure and age in our population study was relatively 
narrow and this may help explain the discrepancy. 
Effects of verapamil and nifedipine on the renin-an•
giotensin-aldosterone system and on plasma volume. 
Plasma renin activity was significantly increased only in 
nonnal subjects after acute administration of nifedipine. On 
the contrary, plasma renin activity did not change signifi•
cantly in hypertensive patients after acute, short-tenn or 
long-tenn administration of verapamil or nifedipine. More•
over, plasma aldosterone concentration and plasma volume 
were not significantly affected by verapamil or nifedipine 
administration in the short-tenn, crossover study or con•
trolled study. These observations seem particularly relevant 
considering that with the exception of the angiotensin-con•
verting enzyme inhibitors, most of the commonly used vaso•
dilators, including hydralazine, diazoxide and minoxidil, 
are known to induce renin stimulation and fluid retention 
(3-5). Our results are in keeping with those of previous 
reports (9,36,37). 
The findings of an inverse correlation between basal plasma 
renin activity and the antihypertensive effect of verapamil 
or nifedipine are partially in agreement with those of a 
previous report by Erne et al. (38); at present, the clinical 
significance of this relation remains to be fully elucidated, 
although it may be argued that the low plasma renin activity 
values indicate a less reactive renin-angiotensin system, in•
sufficient to properly counterregulate the drug-induced de•
crease in blood pressure. 
Echocardiographic findings. Our study demonstrated 
that left ventricular perfonnance as evaluated by echocar•
diographic indexes, such as shortening fraction and mean 
velocity of circumferential fiber shortening, was not de•
pressed by verapamil or nifedipine; actually, shortening 
fraction was enhanced after nifedipine, probably as a result 
of a concomitant adrenergic stimulation. Our results have 
also confinned that the antihypertensive effect of calcium 
antagonist drugs is mainly related to peripheral vasodila•
tation (39), cardiac output being unmodified or slightly in•
creased. 
Clinical implications. Both verapamil and nifedipine 
are safe and effective for the treatment of essential hyper•
tension. They reduce blood pressure through peripheral 
vasodilation, but contrary to other vasodilators, do not in•
duce significant renin stimulation or fluid retention. The 
sympathetic nervous system is influenced in different ways 
by nifedipine and verapamil. Nifedipine may increase ad•
renergic activity in some patients, and therefore, the asso•
ciation with a beta-receptor blocking agent or with alpha-
lACC Vol 7, No 4 
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methyldopa is potentially useful, as previously suggested 
(40,41), The adverse effects related to adrenergic stimula•
tion by nifedipine may be avoided to some extent by the 
use of a sustained release preparation, which produces a 
lower peak serum level of the drug (42), Verapamil usually 
does not induce adrenergic stimulation, In addition, vera•
pamil exerts an antiarrhythmic activity which, according to 
the clinical circumstances, could represent either an advan•
tage or a contraindication, Verapamil should not be com•
bined with beta-receptor blockers because of their common 
depressing effects on cardiac pacemaker cells and atrioven•
tricular conduction, 
Calcium antagonists may be preferable in hypertensive 
patients with clinical signs of ischemic heart disease: more•
over, they can be prescribed to patients with peripheral 
vascular insufficiency and chronic airways disease, Further 
investigation of their use as first line drugs in the long-term 
treatment of patients with hypertension is warranted, 
We thank Carlo Alicandri, MD and Raffaele Fanello, MD for havmg 
referred to u, some of the patients included in the study 
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